People With Osteoporosis Can Walk-BEST to Reduce Fall and Fracture Risk
Recruiting · NCT07621679 · Interventional (participants receive a specific treatment) · Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
View the official record on ClinicalTrials.gov →Interventions studied
Device: Heel2Toe[TM] sensorTechnology-assisted therapeutic walking program
What this trial is about
The aim of the Walk BEST study is to provide evidence that it is feasible to implement the technology assisted gait- focused walking program Walk-BEST™ in older adults with osteoporosis, and that this program is acceptable to this population.
Who can take part
Age range
70 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- men and women 70 years and older
- able to walk independently with or without a walking aid
- experienced a prior fracture after the age of 40, OR two falls in the past 12 months, OR who have a bone mineral density test (done as part of routine clinical evaluation) with a T-score \< -2.5, OR on a Health Canada-approved anti-osteoporosis medication (oral or intravenous bisphosphonate, denosumab, teriparatide, or romozosumab) to reduce fracture risk or on a bisphosphonate drug holiday (planned treatment interruption)
Exclusion criteria
- fracture sustained in the past 12 months
- unable to walk unsupervised because of active medical or neurocognitive reasons
- unable to provide informed consent, or cannot communicate in English or French
Where it is running
1 location listed.
- Research Institute of the McGill University Health Centre - Montreal, Quebec, Canada